stockrow
Saturday 7 November 2026
Export IBO’s income statement to Excel — free account
Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022.
- Revenue
- −57.1%
- EPS
- +99.5%
- Free cash flow
- +167.7%
Quarter to June 2026, against a year earlier
4.10
0.30
−6.82%
Follow IBO
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 24.01% | (119.83%) | (104.15%) | (348.23%) |
+8 more TTM periods Free account |
|
| 4.41% | (69.25%) | (62.81%) | (136.16%) | ||
ROIC |
(22.81%) | (23.66%) | (17.21%) | 0.00% | |
Return on Tangible Assets |
(45.74%) | 981.53% | 1,576.30% | 193.27% | |
Average Days of Receivables |
0.00 | 0.00 | 22.26 | 0.00 | |
Free Cash Flow per Share |
(0.06) | (0.20) | (0.27) | (3.08) | |
Free Cash Flow |
(0.51) | (1.67) | (1.89) | (2.97) | |
| Other line items | |||||
Cash ROIC |
(3.62%) | (11.35%) | (12.15%) | 33.65% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 1.23 | 0.00 | |
Accounts Payable Turnover |
0.83 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
1.55 | 0.00 | — | — | |
Average Days of Payables |
401.07 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
53.25 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
811.43% | 725.64% | 414.63% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
6,202.86% | 5,771.79% | 1,093.90% | 0.00% | |
Share Based Compensation of Revenue |
3,597.14% | 3,646.15% | 15.85% | 0.00% | |
Interest Coverage |
— | — | (5.40) | (27.63) | |
Operating CF/Net income |
(0.64) | 0.13 | 0.16 | 0.07 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 2,017.77 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(0.06) | (0.20) | (0.27) | (3.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026